30 closest matches · ranked by relevance
Thrombocytopenia Associated With Liver Disease
Primary: Percentage of Participants Who Did Not Require a Platelet Transfusion or Any Rescue Procedure for Bleeding After Randomization Following a Scheduled Procedure — 22.9…
Thrombocytopenia
Primary: Number of Participants Who Achieved Platelet Response (Greater Than or Equal to 100 x 10^9/L) by Day 21 of Treatment Period A1 of Core Study — 1; 6; 12; 9 Participants…
Thrombocytopenia Associated With Liver Disease
Primary: Percentage of Participants Who Did Not Require a Platelet Transfusion After Randomization and up to 7 Days Following a Scheduled Procedure — 34.9; 68.6; 33.3; 87.9…
Chronic Liver Disease · Thrombocytopenia
Primary: Percentage of Participants Who Required No Platelet Transfusion Prior to the Primary Invasive Procedure and No Rescue Therapy For Bleeding From Randomization Through 7…
Thrombocytopenia Associated With Chronic Liver Disease
Primary: Percentage of Participants With Platelet Count Greater Than or Equal to 50 x 10^9/L and at Least 20 x 10^9/L Increase From Baseline at Visit 4 — 9.1; 28.6; 63.6; 40.0…
Liver Diseases
Primary: Change From Baseline in Platelet Counts on Day 15 — 24.8; 54.0; 60.0 10^9/Liter
Liver Disease
Primary: Number of Participants That Reached Targeted International Normalized Ratio (INR) Within ±0.1 After First Fresh Frozen Plasma (FFP) Transfusion Completed. — 7; 17…
Thrombocytopenia Related to Chronic Liver Disease
Primary: Percentage of Participants Experiencing Response — 38.9; 31.3; 76.5; 6.3 Percentage of participants
Thrombocytopenia · Hematologic Diseases · Bone Marrow Aplasia
Primary: Number of Patients With Treatment-Emergent Adverse Events (TEAE) — 7; 6; 5 Participants
Thrombocytopenia · Hematologic Diseases
Primary: Number of Participants With Platelet Count Recovery — 20; 22; 6 Participants
Primary Immune Thrombocytopenia
Primary: Percentage of Participants With at Least One Grade 3 or Higher Treatment Emergent Adverse Event (TEAE), Treatment Emergent Serious Adverse Event (SAE), and TEAEs Leading…
Cirrhosis · Chronic Liver Disease
Primary: The Association of HVPG and PUD in Patients With Liver Cirrhosis — 14.5; 15.3 mmHg
Chronic Kidney Disease
Primary: Whole Blood Platelet Aggregation to 0.5 Millimoles Arachidonic Acid — 21.0; 18.0; 0; 0 ohms
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Primary: Number of Participants With a Platelet Response — 12; 0 Participants
Chronic Idiopathic Thrombocytopenic Purpura · Purpura, Thrombocytopenic, Idiopathic
Primary: Number of Responders at Week 6 — 9; 0; 6; 8 Participants
Purpura, Thrombocytopaenic, Idiopathic
Primary: Number of Participants With Bone Marrow (BM) Fibers of MF Grade 0, 1, 2 and 3 on the European Consensus (EC) Scale at Baseline — 150; 9; 0; 0 Participants
Liver Fibrosis
Primary: Median Liver Stiffness Value — 7.70; 6.90 kPa — p=0.043
Idiopathic Thrombocytopenic Purpura
Primary: Number of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) for at Least 6 Out of 8 Weeks, Between Weeks 5 and 12 of Part 1 — 1; 25 Participants…
Thrombocytopenia
Primary: At Least One Day With Grade 2 or Higher Bleeding — 304; 293; 299; 142 participants — p=0.83
Immune Thrombocytopenia
Primary: Cumulative Number of Weeks of Platelet Response — 13.47 cumulative number of weeks
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
Idiopathic Thrombocytopenic Purpura · Purpura, Thrombocytopenic, Idiopathic
Primary: Number of Participants Experiencing an Adverse Event (AE) and/or Serious Adverse Event (SAE) Within the Indicated Category — 19; 6; 5; 0 participants
Thrombocytopenia
Primary: Comparing the Efficacy of Eltrombopaq and Placebo — 15; 5; 9; 0 Participants
Hepatitis C, Chronic
Primary: Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase — 32; 97 participants — p=0.0202
Cardiac Disease · Cardiac Surgery · Cardiopulmonary Bypass
Primary: Amount of Blood Products Transfused — 58; 103 milliliter per kilogram (mL/kg)
Hepatitis C, Chronic
Primary: Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase — 33; 104 participants — p=0.0064
HIV-1 Infection
Primary: Change in sCD14 From Baseline to Week 24 — 35.75; -251.40; -101.75 pg/mL
Hepatitis C, Chronic
Primary: Number of Participants Whose Platelet Count Increased From a Baseline Count of < 80 Gi/L to a Count >=100 Gi/L During Part 1 — 43 Participants
Immune Thrombocytopenia
Primary: Number of Patients for Whom Eltrombopag Increases the Platelet Count to > 50,000/uL — 6; 3; 6; 3 participants
Idiopathic Thrombocytopenic Purpura
Primary: Response Rate — 81.3 percentage of responders